Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Operating Expenses (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Operating Expenses data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 24.63% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $13.6 million, up 21.66%, while the annual FY2024 figure was $10.1 million, 53.22% down from the prior year.
  • Operating Expenses reached $2.7 million in Q3 2025 per COEP's latest filing, down from $4.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $15.7 million in Q1 2022 and bottomed at $100017.0 in Q3 2021.
  • Average Operating Expenses over 5 years is $4.5 million, with a median of $3.0 million recorded in 2022.
  • The widest YoY moves for Operating Expenses: up 11004.82% in 2022, down 77.82% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $13.7 million in 2021, then crashed by 77.82% to $3.0 million in 2022, then increased by 7.52% to $3.3 million in 2023, then tumbled by 33.92% to $2.2 million in 2024, then grew by 23.45% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $2.7 million in Q3 2025, $4.7 million in Q2 2025, and $4.1 million in Q1 2025.